Potent graft-versus-leukemia (GVL) effects can be mediated by donor-derived T cells recognizing minor histocompatibility antigens (mHags) in patients treated with donor lymphocyte infusion (DLI) for relapsed hematologic malignancies after HLA-matched allogeneic stem cell transplantation (alloSCT). Donor-derived T cells, however, may not only induce GVL, but also mediate detrimental graft-versus-host disease (GVHD). Because
HLA-class II is under noninflammatory conditions predominantly expressed on hematopoietic cells, CD4 + T cells administered late after alloSCT may selectively confer GVL without GVHD. Although a broad range of different HLA-class I-restricted mHags have been identified, the first 2 autosomal HLA-class II-restricted mHags have only recently been characterized. By screening a recombinant bacteria cDNA expression library, we identified 4 new HLA-class II-restricted mHags recognized by CD4 + T cells induced in a patient with relapsed chronic myeloid leukemia who achieved long-term complete remission and experienced only mild GVHD of the skin after DLI. All CD4 + T cells were capable of recognizing the mHags presented by HLA-DR surface molecules on primary hematopoietic cells, but not on skin-derived (cytokine-treated) fibroblasts. The selective recognition of hematopoietic cells as well as the balanced population frequencies and common HLA-DR restriction elements make the novel mHags possible targets for development of immunotherapeutic strategies.
INTRODUCTION
Relapsed hematologic malignancies after HLA-matched allogeneic stem cell transplantation (alloSCT) can be efficiently treated with donor lymphocyte infusion (DLI). [1] [2] [3] This beneficial graft-versus-leukemia (GVL) immunoreactivity is mediated by donor T cells directed against minor histocompatibility antigens (mHags). These mHags are polymorphic peptides that differ between patient and donor, and are able to elicit CD8 + or CD4 + donor T-cell responses in the context of self-HLA. 4 A variety of HLA-class Irestricted mHags have been identified, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and the appearance of CD8 + T cells specific for several of these mHags was closely followed by complete remissions of the malignancies, 12, 14, 16, 18 indicating the clinical relevance of these T cells.
Because HLA-class I molecules are expressed on all nucleated cells in malignant and nonmalignant tissues of the patient, CD8 + T cells recognizing mHags in the context of HLA-class I molecules may not only mediate GVL, but also induce detrimental graftversus-host disease (GVHD). GVHD is still the main cause of transplant-related morbidity and mortality, 19 and therefore separating GVL and GVHD is a major objective of immunotherapy after alloSCT. One approach is the use of mHags that are encoded by hematopoiesis-restricted genes such as HA-1 6 and HA-2, 5 to specifically stimulate cytotoxicity of donor-originated CD8 + T cells against the malignant hematopoietic cells of the patient.
It is well established that also CD4 + T cells play an important role in antitumor immunity, both as helper cells indispensable for the induction and maintenance of CD8 + T cells [20] [21] [22] and as effector cells with direct cytolytic activity against HLA-class II + tumor cells. [23] [24] [25] [26] Because under noninflammatory or low-inflammatory conditions HLA-class II molecules are predominantly expressed on hematopoietic cells, stimulating CD4 + T-cell immunity late after alloSCT may be another promising strategy to selectively target residual leukemia without inducing severe GVHD. [27] [28] [29] Although several HLA-class I-restricted mHags have been identified by various methods, [5] [6] [7] [8] 10, 11, [13] [14] [15] [16] [17] 30, 31 the discovery of HLA-class II-restricted mHags proved to be more difficult and was hampered by technical limitations. We developed a method by which recombinant bacteria cDNA expression libraries were used to identify antigens as targets for CD4 + T cells. 32 The feasibility of this method was demonstrated by the recent identification of the first autosomal HLA-class II-restricted mHag LB-PI4K2B-1S. 33 Using a combination of genetic linkage analysis and subsequent fine mapping with single nucleotide polymorphism (SNP) markers, another autosomal HLA-DQ-restricted mHag encoded by the B cellspecific CD19 gene was recently identified. 34 However, identification of more HLA-class II-restricted mHags is required to further elucidate their role in GVL and GVHD, and to explore their use as targets for CD4 + T cells to treat hematologic malignancies.
Here, we present the molecular identification of 4 new HLA-DR-restricted autosomal mHags recognized by CD4 + T cells induced in a patient who was successfully treated with DLI for relapsed chronic myeloid leukemia (CML). Our data show that CD4 + T cells directed against these mHags recognized primary hematopoietic cells, but not skin-derived (cytokine-treated) fibroblasts. These in vitro findings and the clinical observation that a long-lasting complete remission was induced with only limited GVHD of the skin suggest an important role of the novel HLA-DR-restricted mHags in antitumor reactivity.
METHODS

Isolation of hematopoietic cells
Peripheral blood and bone marrow (BM) samples were obtained from patients with hematologic malignancies and healthy persons after approval by the Leiden University Medical Center Institutional Review Board and informed consent according to the Declaration of Helsinki. Mononuclear cells were isolated by Ficoll-Isopaque separation and cryopreserved. Activated CD4 + T cells were isolated from BM of the patient 5 weeks after DLI. BM cells were stained with fluorescein isothiocyanate (FITC)-labeled anti-CD4 (BD Biosciences) and phycoerythrin (PE)-labeled anti-HLA-DR (BD Biosciences) and single cell sorted by flow cytometry. For isolation of patient-derived hematopoietic cells, peripheral blood mononuclear cells (PBMCs) obtained from the patient before alloSCT were stained with FITC-labeled anti-CD14, PE-labeled anti-CD3, and allophycocyanin-labeled anti-CD19 (BD Biosciences), and monocytes (CD14 + ), T cells (CD3 + ) and B cells (CD19 + ) were isolated by flow cytometry. CD34 + CML progenitor cells were isolated from BM cells obtained from the patient during the relapse before DLI by flow cytometric sorting after staining with allophycocyanin-labeled anti-CD34 (BD Biosciences). CD34 + progenitor cells from other patients with CML were isolated by magnetic beads according to the manufacturer's instructions (Miltenyi Biotec). CD33 + /CD14 − acute myeloid leukemia (AML) cells from 3 patients were isolated by flow cytometric sorting after staining with CD14-FITC and CD33-allophycocyanin (BD Biosciences).
Cell culture
Epstein-Barr virus transformed B-cell lines (EBV-LCLs) were cultured in Iscove modified Dulbecco medium (IMDM; Lonza BioWhittaker) with 10% fetal calf serum (FCS; Cambrex), 1% penicillin/streptomycin (Lonza BioWhittaker), and 1.5% L-glutamine (Lonza BioWhittaker). T-cell clones were cultured in IMDM with 5% human serum, 5% FCS, and 100 IU/mL interleukin-2 (IL-2; Chiron), and restimulated every 10 to 20 days with irradiated allogeneic PBMCs and 0.8 μg/mL phytohemagglutinin (Oxoid) as previously described. 14, 16 Immature dendritic cells (DCs) were generated by culturing isolated monocytes in medium with 100 ng/mL granulocyte-macrophage colonystimulating factor (GM-CSF; Novartis) and 500 IU/mL IL-4 (Schering-Plough) for 7 days.
During the final 2 days, 100 ng/mL GM-CSF, 10 ng/mL tumor necrosis factor α (TNF-α; Cellgenix), 10 ng/mL IL-1β (Cellgenix), 10 ng/mL IL-6 (Cellgenix), 1 μg/mL prostaglandin E 2 (Sigma-Aldrich), and 500 IU/mL interferon-γ (IFN-γ; Boehringer-Ingelheim) were added for maturation. Isolated CD34 + CML progenitor cells were modified to leukemic antigen-presenting cells (APCs) as described previously. 35 Fibroblasts were cultured in Dulbecco modified Eagle medium (Lonza, BioWhittaker) with 8% FCS, 1% penicillin/streptomycin, and 1.5% glutamine in the absence or presence of IFN-γ (100 IU/mL) for 5 days. 
Construction of recombinant bacteria cDNA expression library
A recombinant bacterial cDNA expression library was constructed as described previously. 33 In brief, RNA of the patient was isolated with Trizol (Invitrogen) and purified (RNeasy kit; QIAGEN). cDNA was synthesized with oligo-dT and random primers, respectively. Both primers contained an AscI restriction site. After cDNA synthesis, BamHI-EcoRI (Stratagene) adapters were ligated, followed by digestion with AscI and size fragmentation by column chromatography. cDNA fragments were ligated into BamHI and
AscI restriction enzyme sites of vector pKE-1, 36 which contains an isopropyl β-Dthiogalactoside (IPTG)-inducible tac promoter and resistance genes for ampicillin and kanamycin. Vectors were electroporated into Escherichia coli BL21 (DE3) and recombinant bacteria were selected for ampicillin resistance.
Screening of recombinant bacteria cDNA expression library
Pools of 50 to 100 recombinant bacteria were screened for T-cell recognition, as described previously. 33 Bacteria were grown to 600-nm optical density of 0.5 with 50 μg/mL ampicillin (Sigma-Aldrich) and protein expression was induced by 1 mM IPTG (Promega).
Subsequently, bacteria were opsonized by adding human serum with 17% (vol/vol) complement (Sigma-Aldrich) and incubated for 1 hour. EBV-LCLs of the fully HLAmatched donor (3 × 10 4 cells/well) were pulsed with complement-opsonized bacteria in IMDM with 10% FCS and 30 μg/mL gentamycin (Sigma-Aldrich) overnight at 37°C.
Mixes of up to 3 CD4 + T-cell clones (3 × 10 3 cells/well per clone) were coincubated with bacteria-pulsed EBV-LCLs for 20 hours. Supernatants were harvested for IFN-γ ELISA. In a second round, single bacterial clones derived from a positive pool were screened for Tcell recognition. Positive bacterial clones were grown overnight and plasmids were isolated by the plasmid mini prep kit (QIAGEN). Inserted cDNA fragments were sequenced using vector-specific primers.
Isolation and retroviral transduction of HLA-DR alleles
Total RNA of patient-derived EBV-LCLs was obtained using Trizol (Invitrogen) and transcribed into cDNA by reverse transcriptase (Invitrogen) using oligo-dT primers (Roche Diagnostics). HLA-DR genes were amplified with HLA-DRB1-and HLA-DRB3-specific primers. Polymerase chain reaction (PCR) products were cloned into retroviral vector MP71, which contains the marker nerve growth factor receptor (ΔNGF-R). 37 PCR products were verified by sequencing. Wild-type φnx A packaging cells were transfected with these vectors as previously described, 37 with the exception that the Fugene HD transfection kit (Roche Diagnostics) was used. Viral supernatants were used for transduction of EBV-LCLs on plates coated with recombinant human fibronectin CH 296 (Takara Shuzo) as previously described. 37 All EBV-LCLs showed retroviral transduction efficiencies of 3% to 7% based on staining with PE-conjugated anti-ΔNGF-R (BD Biosciences).
SNP genotyping assays
Genomic DNA was isolated from 1400 patient and donor samples (PBMCs or BM cells) by the Gentra Systems PureGene genomic isolation kit (Biocompare). The SNPs rs751019 (PTK2B), rs2236225 (MTHFD1), and rs12692566 (LY75) 38 were analyzed using SNP genotyping assay (Applied Biosystems) containing forward and reverse primer for amplification and 2 TaqMan MGB probes labeled with VIC and FAM dyes to detect the different alleles. SNP rs2236410 (MR1) was analyzed using allele-specific primers labeled with VIC and FAM dyes, respectively (KBioScience). Genotyping was performed according to the manufacturer's instructions.
Quantitative RT-PCR
Quantitative real-time reverse-transcriptase (RT)-PCR was performed as described previously. 14 
RESULTS
Isolation and characterization of mHag-specific CD4 + T-cell clones
We analyzed the specificity of the CD4 + T-cell response induced in a patient with relapsed CML after HLA-matched alloSCT who responded to DLI with complete donor chimerism and remission of the leukemia, and developed only mild GVHD of the skin. CD4 + T cells were single cell sorted from bone marrow mononuclear cells obtained 5 weeks after DLI based on expression of the activation marker HLA-DR ( Figure 1A) . A total number of 25
CD4 + T-cell clones were shown to recognize mHags based on differential recognition of patient and donor EBV-LCLs in an overnight IFN-γ ELISA. By pulsing donor EBV-LCLs with a peptide comprising previously identified mHag LB-PI4K2B-1S, 9 of the 25 T-cell clones were shown to be specific for HLA-DQB1*0603-restricted LB-PI4K2B-1S (data not shown). Of the 16 remaining T-cell clones, 8 clones (55, 62, 78, 79, 80, 87, 92, and 100) produced high levels of IFN-γ (> 250 pg/mL) upon incubation with patient EBV-LCLs ( Figure 1B) , and were selected for further characterization.
All 8 T-cell clones showed specific lysis of patient, but not donor, EBV-LCLs in a 10-hour 51 chromium release assay ( Figure 1C ), and produced IFN-γ, IL-13, IL-5, and IL-2 ( Figure   1D ), but not IL-4, IL-6, IL-10, IL-12, IL-17A, TNF-α, granulocyte CSF, or transforming growth factor β1 as determined by multicytokine ELISA.
To The capacity of the mHag-specific CD4 + T cells to recognize nonmalignant and malignant hematopoietic cells was determined by IFN-γ ELISA. B cells, T cells, and monocytes were purified from PBMCs of the patient before alloSCT, and tested for recognition. In addition, immature and mature dendritic cells (DCs) were generated from isolated monocytes in vitro, and malignant CD34 + CML progenitor cells were purified from BM obtained from the patient during the relapse after alloSCT before treatment with DLI. (D) CD4 + T-cell clones were tested for cytokine release by multicytokine ELISA. Release of IL-2, IL-5, IL-13, and IFN-γ in 50-μL single supernatants is shown (ng/mL). CD4 + T-cell clones did not produce IL-4, IL-6, IL-10, IL-12, IL-17A, TNF-α, granulocyte CSF, and transforming growth factor β1 (data not shown). Figure 2A shows that all T-cell clones strongly recognized mature DCs, expressing high levels of HLA-class II and costimulatory molecules, whereas monocytes and immature DCs were recognized at variable levels. Clones 62, 78, 80, and 87 weakly recognized monocytes and immature DCs, whereas these cells were strongly recognized by clone 100. All T-cell clones recognized high HLA-class II-expressing B cells, although to a different extent, whereas T cells, lacking expression of HLA-class II, were not recognized ( Figure 2B ).
Purified CD34 + CML progenitor cells from the patient were weakly recognized by clones 62, 78, and 80, whereas strong recognition was observed for clones 87 and 100 ( Figure 2B ).
In addition to purified CD34 + CML progenitor cells of the patient, CD34 + cells were isolated from other patients with CML and differentiated to immature and mature leukemic
APCs. The data in Figure 2C show that, upon induction of an APC phenotype in vitro, CML cells were recognized by all T-cell clones.
In conclusion, these data suggest that the mHag-specific CD4 + T cells have been induced in this patient by malignant CML cells with mature APC phenotype and that the CD4 + T cells 
Identification of 4 HLA-class II-restricted mHags as targets for CD4 + T cells
To identify the mHags recognized by CD4 + T-cell clones 62, 78, 80, 87, and 100, recombinant bacterial cDNA expression libraries were constructed from EBV-LCLs of the patient, and screened for T-cell recognition as previously described. 33 To identify the epitope recognized by clone 62, 3 overlapping 19-mer peptides all comprising the R at position 39 were synthesized and tested for T-cell recognition ( Figure   3A ). Two of these peptides stimulated IFN-γ release by clone 62. A 15-mer peptide comprising amino acids shared by the 2 19-mer peptides also stimulated IFN-γ release, whereas a 15-mer peptide containing the donor variant H at position 39 was not recognized ( Figure 3A) . Serial truncations of the 15-mer peptide at the N and C termini led to the identification of a minimal 12-mer YFRLGVSDPIRG peptide (amino acids 29-40), designated LB-MR1-1R ( Figure 3A) .
LB-PTK2B-1T
Screening the same fraction of the random-primed cDNA library revealed 2 other bacterial pools that stimulated IFN-γ release by clone 78. Subcloning of these 2 pools revealed 2 cDNAs containing 813-to 2558-bp and 2318-to 3414-bp regions of the gene encoding "protein tyrosine kinase 2 beta, variant 4" (PTK2B; GenBank accession no. NM_173175).
The 241-bp region that was shared by the 2 cDNAs contained only 1 known missense SNP Figure 3B ).
LB-LY75-1K
In another screening containing shorter fragments of the random cDNA library, 3 bacterial Following a similar strategy as described for LB-MR1-1R and LB-PTK2B-1T, a minimal epitope of 10 amino acids (GITYRNKSLM) of LB-LY75-1K was shown to be recognized by clone 80 ( Figure 3C) . A 15-mer peptide containing the donor variant N at position 1321 did not stimulate the release of IFN-γ.
LB-MTHFD1-1Q
Finally, the fraction with the largest fragments of the oligo-dT-primed cDNA library was screened for T-cell recognition. Three bacterial pools stimulated IFN-γ release by clone 87.
Subcloning of these 3 pools revealed 2 cDNAs containing 3-to 3116-bp and 1166-to 3116bp regions of the gene encoding "methylene tetrahydrofolate dehydrogenase (NADP + dependent) 1" (MTHFD1; GenBank accession no. NM_005956). In the 1951-bp region Figure 3D ).
Frequencies of HLA-class II-restricted mHag-specific T-cell clones
To 
Population frequencies of HLA-class II-restricted mHags
To determine the population frequencies of the new HLA-class II-restricted mHags, SNP genotyping assays for rs2236410 (LB-MR1-1R), rs751019 (LB-PTK2B-1T), rs2236225
(LB-MTHFD1-1Q), and rs12692566 (LB-LY75-1K) were performed for 1400 patient and donor samples available at our laboratory. The analysis showed balanced population frequencies of 25% (LB-MR1-1R), 33% (LB-LY75-1K), 68% (LB-MTHFD1-1Q), and 70% (LB-PTK2B-1T; Table 1 ). These population frequencies slightly differ from the white population frequencies in the dbSNP database, 38 which were 33%, 40%, 50%, and 60%, respectively.
Identification of the HLA-class II restriction elements
Based on the SNP genotyping results, a panel of mHag + EBV-LCLs sharing one or more HLA-class II alleles with the patient was composed and tested for T-cell recognition. The data strongly suggested HLA-DRB3*0202, -DRB3*0101, -DRB1*1301, and -DRB1*0301 as restriction elements for LB-MR1-1R, LB-PTK2B-1T, LB-LY75-1K, and LB-MTHFD1-1Q, respectively (data not shown). Restriction by these HLA-class II alleles was confirmed by retroviral transduction of mHag + EBV-LCLs lacking the appropriate HLA molecule with patient-derived cDNAs encoding the respective HLA-class II molecules (Figure 4 ).
Tissue-specific recognition of HLA-class II-restricted mHags
CD33 + /CD14 − cells from mHag + patients with AML expressing the appropriate HLA-DR molecules were purified by flow cytometry and tested for T-cell recognition. Figure 5 shows recognition of primary AML cells by all mHag-specific CD4 + T-cell clones. In addition, fibroblasts derived from a skin biopsy of the patient were cultured with and without IFN-γ and tested for recognition. Flow cytometric analysis demonstrated significant up-regulation of HLA-DR surface molecules after treatment with IFN-γ ( Figure   6A ). Similar results were obtained for skin-derived keratinocytes. None of the CD4 + T-cell clones, however, was capable of recognizing (IFN-γ-treated) fibroblasts ( Figure 6B ).
MHag + keratinocytes expressing the appropriate HLA-DR molecule were available only for clones 62 and 78. Both clones failed to recognize (IFN-γ-treated) keratinocytes (data not shown), demonstrating that the novel mHags are efficiently presented by HLA-DR surface molecules on various hematopoietic cells, including primary AML cells, but not on nonhematopoietic fibroblasts and keratinocytes.
Tissue-specific expression of the mHag-encoding genes
To investigate the tissue distribution of the mHag-encoding genes, non-hematopoietic cells of different origins were cultured (fibroblasts, keratinocytes, biliary epithelial cells, proximal tubular epithelial cells, and gut epithelial cells) or isolated (hepatocytes), and gene expression was analyzed and compared with hematopoietic cells (PBMCs and EBV-LCLs) by quantitative real-time RT-PCR. The data showed overexpression of the LY75 (> 10-fold) and PTK2B (> 4-fold) genes in hematopoietic versus non-hematopoietic cells ( Table 2) . 
Expression of the MR1 gene was comparable between hematopoietic cells and fibroblasts,
DISCUSSION
In patients with relapsed hematopoietic malignancies after alloSCT, infusions with donor lymphocytes have proven to mediate potent GVL effect resulting in complete remissions. [1] [2] [3] In this study, we demonstrated that CD4 + T cells directed against 6 different HLA-class IIrestricted mHags, including previously identified HLA-DQ-restricted mHag LB-PI4K2B-1S, 33 were induced in a patient with relapsed CML after alloSCT who showed long-term complete remission after treatment with DLI.
A broad range of HLA-class I-restricted mHags has been identified using a variety of techniques, including screening of plasmid cDNA libraries, 7, 10, 14, 15, 17 elution of HLA-bound peptides, 5, 6, 8, 11, 13, 16 genetic linkage analysis, 9, 12 and recently whole genome association scans. 30, 31 Most of these techniques did not allow or were difficult to adapt for identification of HLA-class II-restricted mHags. By screening a recombinant bacteria cDNA library, 32 we could now identify 4 unknown CD4 + T-cell specificities. This technique is not only extremely efficient for identification of mHags, but may also have broad value for identification of nonpolymorphic antigens in antitumor or autoimmunity.
Thus far, most nonpolymorphic HLA-class II-restricted epitopes have been characterized by screening antigens that were known targets for CD8 + T cells or antibodies. 40 Although this approach led to the identification of useful targets for T-cell therapy, HLA-class II epitopes from unknown and perhaps clinically more relevant antigens might have been missed.
It is well established that CD4 + T cells are required for efficient induction of in vivo immunity. 21, 22 In this study, all CD4 + T-cell clones showed not only recognition, but also specific lysis of patient-derived EBV-LCLs, suggesting a role in antitumor immunity as effector cells. Isolated CML progenitor cells, however, were strongly recognized only by Tcell clones 87 and 100, whereas all mHag-specific T-cell clones showed strong recognition of CML cells upon induction of an APC phenotype. Therefore, we hypothesize that all mHag-specific CD4 + T cells were key players as helper cells in the induction of antitumor phenotype. The latter possibility seems unlikely, because no difference in expression of HLA-DR and various costimulatory (CD40, CD80, CD83, CD86) molecules was observed between CD34 + CML and AML cells (data not shown). A third, and perhaps more likely, explanation is a difference in processing and presentation of endogenous antigens into the HLA-class II pathway in CML-APCs compared with CML progenitor cells. This is supported by recent findings suggesting that maturation of APCs could enhance HLA-class II-restricted antigen presentation of endogenous proteins. 41 In several patients treated with alloSCT, high frequencies of mHag-specific CD4 + T cells have been shown to precede and closely correlate with the onset of clinical GVHD. 23, [42] [43] [44] [45] Although constitutive HLA-class II expression is restricted to hematopoietic cells, expression can be induced on non-hematopoietic cells by proinflammatory cytokines. CD4 + T cells recognizing mHags in HLA-class II may therefore contribute to development of GVHD when high levels of proinflammatory cytokines are released as a consequence of conditioning regimens or high pathogenic loads early after transplantation. 46 Under noninflammatory conditions, however, mHag-specific CD4 + T cells may exert a selective GVL effect without GVHD. This is supported by one of our recent studies demonstrating high numbers of HLA-DP-specific alloreactive CD4 + T cells in a patient who responded to DLI without GVHD late after HLA-DP-mismatched alloSCT, 29 as well as by clinical studies showing that CD8 + T-cell depletion reduces the incidence of GVHD associated with DLI without adversely affecting conversion to donor hematopoiesis. 27, 28 We here isolated mHag-specific CD4 + T cells from a patient who responded to DLI with only mild GVHD more than 1 year after alloSCT. Our in vitro data demonstrated no recognition of fibroblasts and keratinocytes by the mHag-specific CD4 + T cells, even after up-regulation of HLA-DR by IFN-γ. For LY75 and PTK2B, the lack of recognition can be explained by low gene expression levels in non-hematopoietic cells. For MR1 and MTHFD1, however, gene expression is similar between hematopoietic and nonhematopoietic cells. Our data therefore demonstrate that gene expression is not predictive
for T-cell recognition of non-hematopoietic cells, and do not support a role for these mHagspecific CD4 + T cells in development of GVHD. The lack of recognition of nonhematopoietic cells by the mHag-specific CD4 + T cells may be explained by altered protein translation or degradation or inefficient processing and presentation of the novel mHags into the HLA-class II pathway, as postulated for isolated CML progenitor cells.
All 4 novel mHags have potential relevance as targets in antitumor immunity after HLAmatched alloSCT. LB-LY75-1K and LB-PTK2B-1T are attractive based on overexpression of their genes in hematopoietic versus non-hematopoietic cells, whereas LB-MTHFD1-1Q may be useful as direct target for CD4 + T cells against CD34 + CML progenitor cells. Of special interest may be the PTK2B gene, also known as Pyk2/RAFTK/FAK2/CAKβ. The nonreceptor tyrosine kinase has been reported to play a role in dysregulation of various cellular processes in tumor cells, and may be interesting for immunotherapy as potential tumor-associated antigen. [47] [48] [49] [50] [51] This is supported by the finding that antibodies against PTK2B have been observed in 3 of 19 patients with CML who responded to CD4 + DLI. 52 Because PTK2B is an intracellular protein, antibodies against PTK2B are not expected to been identified as targets for CD4 + T cells isolated from 1 patient, and it therefore remains to be shown whether these mHags are broadly immunogenic in other mHag-disparate patient-donor pairs.
In conclusion, our detailed analysis of the in vivo induced CD4 + T-cell response after DLI provides insight into the role of CD4 + T cells as helper and/or effector cells in therapeutic alloreactivity. The findings establish a basis for fundamental understanding of these phenomena, which is required for optimal use of HLA-class II-restricted mHags in the development of new T cell-based immunotherapies.
